# Millennium Pharmaceuticals

**Canonical:** https://apis.io/providers/millennium-pharmaceuticals/  
**APIs profiled:** 0

Millennium Pharmaceuticals was a biopharmaceutical company based in Cambridge, Massachusetts, focused on oncology and inflammation, best known for developing the cancer drug Velcade (bortezomib). Backed early by Kleiner Perkins, it was acquired by Takeda Pharmaceutical Company in 2008 for $8.8B and its brand was retired to "Takeda Oncology" in 2013; it no longer operates as an independent company. Surfaced in the API Evangelist network as a VC-portfolio stub. This is a research/company profile with no independent developer API surface — the pipeline confirmed the provider publishes no public API, developer portal, SDKs, or event/webhook surface.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Healthcare, Biopharmaceutical, Oncology, Pharmaceuticals, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/millennium-pharmaceuticals/). Scores are computed from the provider's own public artifacts under a published rubric.